This site is intended for healthcare professionals

FDA indicates phase III Marigold Study of oral ganaxolone supports filing in CDKL5 deficiency disorder.- Marinus Pharma

Read time: 1 mins
Last updated:15th Jan 2021
Published:15th Jan 2021
Condition: Epilepsy- Paediatric Genetic
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest